Bristol-Myers, ZymoGenetics Hit With Suit Over Merger
ZymoGenetics Inc. shareholders have launched a class action alleging the drug developer and Bristol-Myers Squibb are trying to lowball stockholders as they work to complete an $885 million merger....To view the full article, register now.
Already a subscriber? Click here to view full article